PT - JOURNAL ARTICLE AU - Blank, Paul S. AU - Golding, Adriana E. AU - Benavides, Ivonne Morales AU - Waters, Hang AU - Mekhedov, Elena AU - Bezrukov, Ludmila AU - Wachter, Rebecca D. AU - Mikhailenko, Irina AU - Brown, Robert H. AU - Bönnemann, Carsten G. AU - Demidowich, Andrew P. AU - Jain, Minal S. AU - Yanovski, Jack A. AU - Zimmerberg, Joshua TI - Physical activity-correlated changes in plasma enzyme concentrations in fragile sarcolemmal muscular dystrophies AID - 10.1101/2022.04.01.22273213 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.01.22273213 4099 - http://medrxiv.org/content/early/2022/04/05/2022.04.01.22273213.short 4100 - http://medrxiv.org/content/early/2022/04/05/2022.04.01.22273213.full AB - Background and Objectives Muscular dystrophies associated with decreased sarcolemma integrity lack validated clinical measures of sarcolemma fragility that can be used to assess disease progression and the effects of therapies designed to reduce sarcolemma fragility. We conducted a pilot study to test the hypothesis that physical activity leads to significant changes in muscle-derived plasma enzymes in participants with “fragile sarcolemmal muscular dystrophies” (FSMD).Methods We enrolled ambulatory individuals clinically affected with genetically confirmed FSMD neither taking anti-inflammatory medications nor having relevant co-morbidities for an inpatient study. Over five days, blood samples at 20 time points were obtained. Plasma enzymes alanine and aspartate aminotransferase (ALT, AST), creatine kinase (CK), and lactate dehydrogenase (LDH), all found in muscle, were measured before and after routine morning activities and motor function testing. Analysis of Z-transformed time series data led to feature and kinetic models that revealed activity-dependent feature and kinetic parameters.Results Among the 11 enrolled participants, (LGMD Type 2B/R2 Dysferlin-related (4F/1M), LGMD Type 2L/R12 Anoctamin-5-related (3F/2M), LGMD Type 2I/R9 FKRP-related (1M)), plasma enzymes increased with activity. The average % change +/- SEM with morning activity across all participants was ALT 12.8 ± 2.8%, AST 11.6 ± 2.9%, CK 12.9 ± 2.8%, and LDH 12.2 ± 3.9%, suggesting the increases originate from the same stimulated source, presumably skeletal muscle. For ALT, AST, CK, and LDH, characteristic kinetic features include (a) elevated enzyme activities on arrival that decreased overnight; (b) a longer decay trend observed over the week, and (c) for ALT, AST, and CK, a similar decay trend observed with post-morning activity blood draws.Discussion Controlled activity-dependent changes in plasma ALT, AST, and CK on time scales of days to weeks can serve as common outcome measures for sarcolemma integrity and may be efficient and effective tools for monitoring disease progression and treatment efficacy for both individuals and patient populations. In addition, this study provides data that may benefit patient management as it can inform guidance on duration and type of activity that minimizes muscle damage.Competing Interest StatementP.S. Blank reports no disclosures relevant to the manuscript. A.E. Golding reports no disclosures relevant to the manuscript. I.M. Benavides reports no disclosures relevant to the manuscript. H. Waters reports no disclosures relevant to the manuscript. E. Mekhedov reports no disclosures relevant to the manuscript. L. Bezrukov reports no disclosures relevant to the manuscript. R.D. Wachter reports no disclosures relevant to the manuscript. I. Mikhailenko reports no disclosures relevant to the manuscript. R.H. Brown received consulting fees from Apic-Bio, Inc. and had equity in Apic-Bio, Inc. and Amylyx. C.G. Bönnemann reports no disclosures relevant to the manuscript. A.P. Demidowich received grant support from DexCom, Inc. for clinical trials evaluating glycemic control in patients with Type 1 Diabetes, unrelated to the current manuscript. M.S. Jain reports no disclosures relevant to the manuscript. J.A. Yanovski received grant support for clinical trials of setmelanotide in obesity from Rhythm Pharmaceuticals, Inc, received grant support for clinical trials of diazoxide choline controlled release in Prader-Willi syndrome from Soleno Therapeutics, Inc, and received colchicine and placebo for clinical trials in obesity from Hikma Pharmaceuticals, all unrelated to the current manuscript. J Zimmerberg reports no disclosures relevant to the manuscript.Clinical Protocols https://clinicalstudies.info.nih.gov/protocoldetails.aspx?id=13-CH-0112&&query=muscular Funding StatementThis research was funded by the Intramural Research Program of NICHD, NIH (ZIAHD001415, JZ)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards of the National Institutes of Health's Clinical Center and the Eunice Kennedy Shriver's National Institute of Human Development gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data not published within this article is available by request from the corresponding author.